What is Leerink Partnrs’ Forecast for IDYA Q1 Earnings?

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) – Research analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of IDEAYA Biosciences in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst A. Berens expects that the company will earn ($0.66) per share for the quarter. Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for IDEAYA Biosciences’ current full-year earnings is ($2.45) per share. Leerink Partnrs also issued estimates for IDEAYA Biosciences’ Q2 2025 earnings at ($0.70) EPS, Q3 2025 earnings at ($0.63) EPS, Q4 2025 earnings at ($0.75) EPS, FY2025 earnings at ($2.74) EPS, FY2026 earnings at ($2.81) EPS and FY2027 earnings at ($2.70) EPS.

A number of other analysts have also commented on the company. Royal Bank of Canada reiterated an “outperform” rating and set a $61.00 price target on shares of IDEAYA Biosciences in a report on Wednesday, January 15th. UBS Group started coverage on IDEAYA Biosciences in a research note on Thursday, October 24th. They set a “buy” rating and a $50.00 target price on the stock. Leerink Partners lowered shares of IDEAYA Biosciences from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $41.00 to $27.00 in a research report on Tuesday, November 5th. Wedbush reaffirmed an “outperform” rating and issued a $52.00 price objective on shares of IDEAYA Biosciences in a research report on Tuesday, December 17th. Finally, Oppenheimer reissued an “outperform” rating and set a $53.00 target price on shares of IDEAYA Biosciences in a research report on Tuesday, October 29th. Two analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, IDEAYA Biosciences presently has an average rating of “Moderate Buy” and a consensus target price of $53.67.

IDEAYA Biosciences Stock Down 2.5 %

Shares of NASDAQ IDYA opened at $22.42 on Monday. The company has a market capitalization of $1.94 billion, a PE ratio of -9.62 and a beta of 0.82. The stock’s 50 day moving average price is $24.94 and its 200-day moving average price is $30.52. IDEAYA Biosciences has a twelve month low of $22.10 and a twelve month high of $47.74.

Institutional Investors Weigh In On IDEAYA Biosciences

Several institutional investors have recently made changes to their positions in IDYA. Covestor Ltd raised its stake in shares of IDEAYA Biosciences by 23,050.0% during the 3rd quarter. Covestor Ltd now owns 926 shares of the company’s stock valued at $29,000 after purchasing an additional 922 shares during the period. Allworth Financial LP grew its holdings in IDEAYA Biosciences by 800.0% during the 3rd quarter. Allworth Financial LP now owns 900 shares of the company’s stock valued at $29,000 after buying an additional 800 shares in the last quarter. R Squared Ltd bought a new stake in shares of IDEAYA Biosciences during the fourth quarter valued at about $35,000. US Bancorp DE lifted its holdings in shares of IDEAYA Biosciences by 67.2% in the third quarter. US Bancorp DE now owns 1,714 shares of the company’s stock worth $54,000 after buying an additional 689 shares in the last quarter. Finally, KBC Group NV boosted its position in shares of IDEAYA Biosciences by 29.1% in the third quarter. KBC Group NV now owns 2,274 shares of the company’s stock valued at $72,000 after acquiring an additional 513 shares during the period. Hedge funds and other institutional investors own 98.29% of the company’s stock.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.